| Ytd | -70.44% | |
| 1y | -71.53% |
| Open | Prev Close | 0.38 | Low | High | Mkt Cap | 72.96M | |||
| Vol | 0.00 | Avg Vol | 2.58M | EPS | -0.18 | P/E | N/A | Forward P/E | 178.00 |
| Beta | 1.62 | Short Ratio | 14.20 | Inst. Own | 81.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 0.35 | 200-d Avg | 0.78 | 1yr Est | 6.00 |
HRTX News
On September 23, 2026 (the "Effective Date"), Heron Therapeutics, Inc., a Delaware corporati
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the ana
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad
HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a
Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stag
HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-sta
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-sta
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the ana
Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.10) per share which missed the ana
Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stag
Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers t
Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.02) per share which missed the ana
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:H
Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.00 million-$163.00 million t
Heron Therapeutics (NASDAQ:HRTX) reported quarterly earnings of $0.01 per share which beat the analy
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintai
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintai
Financial Guidance for 2025 Item2025 Full-Year Guidance for Net Revenue and Adjusted EBITDA(in milli
Heron Therapeutics (NASDAQ:HRTX) reported quarterly earnings of $0.02 per share which beat the analy
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintai
The district court decision concludes the litigation initiated in July 2022 in response to Fresenius
Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers t
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which met the analys
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session a
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for it
Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx ann
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $